Literature DB >> 28930378

The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis.

Samira Behboudi-Gandevani1, Mina Amiri1, Razieh Bidhendi Yarandi1,2, Mahsa Noroozzadeh1, Maryam Farahmand1, Marzieh Rostami Dovom1, Fahimeh Ramezani Tehrani1.   

Abstract

BACKGROUND AND
OBJECTIVE: Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disorder associated with metabolic syndrome (MetS). The aim of this systematic review and meta-analysis was to provide the most reliable estimate risk of MetS in women with PCOS, compared to healthy controls.
METHODS: A comprehensive literature search was performed in PubMed [including Medline], Web of Science and Scopus databases for retrieving articles in English language on the prevalence/incidence and odds of MetS in women with PCOS compared to healthy controls. Mantel-Haenszel methods of meta-analysis were used to present results in terms of the pooled odds ratio (OR) (95% confidence interval [CI]) using fixed/random-effects models with/without the publication bias correction, based on the various subgroups of age and study methods. Newcastle-Ottawa Scaling and The Cochrane Collaboration's risk of bias assessment tool were used to evaluate the quality of studies included.
RESULTS: The search strategy yielded 2759 potentially relevant articles of which 44 articles were included for meta-analysis. Results of the meta-analysis demonstrated that the patients with PCOS regardless of age, BMI and recruitment sources of samples had higher odds of MetS compared to healthy controls (OR 2.5, 95% CI 2.0-3.2). However, adolescents with PCOS had an increased odds of MetS compared to healthy adolescent controls in population- and nonpopulation-based studies (OR 4.7, 95% CI 1.8-11.9; OR 6.1, 95% CI 6.0- 6.1, respectively). However, the odds of MetS had no differences between adults with PCOS compared to healthy controls in population-based studies. These results were confirmed by the subgroup meta-analysis of some studies using age and BMI adjustment/matching. In addition, subgroup analysis based on diagnostic criteria of PCOS showed that the OR of MetS in PCOS using NIH criteria was higher than AES and Rotterdam criteria (Pooled Overall OR based on NIH criteria = 6.05, 95% CIL: 6.0-6.04).
CONCLUSION: These findings provide some information on the real features and a broader view of this syndrome that also helps clarify conflicting results documented in the literature. Accordingly, in prevention strategies, routine screening for metabolic syndrome is suggested for adolescents with PCOS.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  metabolic syndrome; polycystic ovary syndrome; systematic review and meta-analysis

Mesh:

Year:  2017        PMID: 28930378     DOI: 10.1111/cen.13477

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  16 in total

1.  Age at Onset of Metabolic Syndrome Among Women With and Without Polycystic Ovary Syndrome-Like Status.

Authors:  Qing Peng; Carrie A Karvonen-Gutierrez; John F Randolph; Bin Nan; Daniel McConnell; Siobán D Harlow
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

2.  Polycystic Ovarian Syndrome: An Autobiographical Case Report of an Often Overlooked Disorder.

Authors:  Vithi Hitendra Patel
Journal:  Cureus       Date:  2022-01-12

3.  Decreased Sex Hormone-Binding Globulin Indicated Worse Biometric, Lipid, Liver, and Renal Function Parameters in Women with Polycystic Ovary Syndrome.

Authors:  Xi Luo; Xin-Ming Yang; Wang-Yu Cai; Hui Chang; Hong-Li Ma; Yan Peng; Xiao-Ke Wu
Journal:  Int J Endocrinol       Date:  2020-06-25       Impact factor: 3.257

4.  Correlation Between Recovery of Menstrual Cycle and Improvement of Glucose and Lipid Metabolism in Patients with Sleeve Gastrectomy in a Small Chinese Cohort Sample.

Authors:  Yu Ran; Qiang Yi; Cong Li
Journal:  Diabetes Metab Syndr Obes       Date:  2020-12-01       Impact factor: 3.168

5.  Oxidative stress and metabolic markers in pre- and postnatal polycystic ovary syndrome rat protocols.

Authors:  Lady Serrano Mujica; Alessandra Bridi; Ricardo Della Méa; Vitor Braga Rissi; Naiara Guarda; Rafael Noal Moresco; Melissa Orlandin Premaor; Alfredo Quites Antoniazzi; Paulo Bayard Dias Gonçalves; Fabio Vasconcellos Comim
Journal:  J Inflamm Res       Date:  2018-05-15

6.  Oxidative stress and biochemical markers in prenatally androgenized sheep after neonatal treatment with GnRH agonist.

Authors:  Jandui Escariãoda Nóbrega; Joabel Tonelotto Dos Santos; Lady K Serrano-Mujica; Guilherme Bochi; Rafael Noal Moresco; Vitor Braga Rissi; Werner Giehl Glanzner; Felipe W Langer; Alfredo Quites Antoniazzi; Paulo Bayard Dias Gonçalves; Melissa O Premaor; Fabio V Comim
Journal:  J Inflamm Res       Date:  2019-03-06

7.  Serum testosterone acts as a prognostic indicator in polycystic ovary syndrome-associated kidney injury.

Authors:  Yali Song; Wenting Ye; Huiyun Ye; Tingting Xie; Weiwei Shen; Lili Zhou
Journal:  Physiol Rep       Date:  2019-08

Review 8.  Blood pressure in postmenopausal women with a history of polycystic ovary syndrome.

Authors:  Katarzyna Doroszewska; Tomasz Milewicz; Sandra Mrozińska; Jarosław Janeczko; Radosław Rokicki; Marek Janeczko; Damian Warzecha; Piotr Marianowski
Journal:  Prz Menopauzalny       Date:  2019-06-14

Review 9.  Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment.

Authors:  Fahimeh Ramezani Tehrani; Mina Amiri
Journal:  Int J Endocrinol Metab       Date:  2019-07-27

10.  Chinese herbal medicine on treating obese women with polycystic ovary syndrome: A systematic review and meta-analysis protocol.

Authors:  Ning Ding; Rensong Yue; Lizhen Wang; Hongjing Yang
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.